查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1853243

不孕症治療市場按產品類型、治療類型、診斷和最終用戶分類 - 全球預測 2025-2032

Infertility Treatment Market by Product Type, Treatment Type, Diagnosis, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，不孕症治療市場規模將成長 143 億美元，複合年成長率為 11.61%。

主要市場統計數據
基準年2024年 59.3億美元
預計年份：2025年 65.8億美元
預測年份 2032 143億美元
複合年成長率（%） 11.61%

從策略層面介紹臨床進展、病患行為轉變和營運壓力如何重新定義整個醫療保健相關人員生育治療的優先事項。

不孕症治療領域正經歷臨床創新、患者人口結構變化和護理服務模式演變的融合，這共同為醫療保健提供者、供應商和支付方帶來了機會和挑戰。

在臨床方面，檢測設備、冷凍保存通訊協定和輔助療法的進步提高了治療週期效率，並為過去難以治癒的病例拓展了治療選擇。同時，患者的期望也在改變。日益增強的意識、延遲交付以及對個人化診療路徑的需求，促使醫療機構拓展服務範圍，並加大對病患體驗的投入。在經濟方面，資源分配壓力和不穩定的報銷政策要求診所和醫院在設備和耗材的資本投資與營運效率提升之間取得平衡。因此，相關人員必須將臨床優先事項與切合實際的經營模式結合，以維持成長並取得可衡量的成果。

一場變革性的轉變將重新定義整個生育生態系統的臨床實踐、供應鏈韌性、以病人為中心的服務以及政策獎勵。

生育治療領域正在發生變化，這些變化同時也改變臨床實務、供應鏈和照護模式。

首先，實驗室自動化和數位成像技術正在加速生產，同時提高胚胎培養工作流程的一致性。這些技術變革迫使診所重新思考人員配置模式和培訓重點。其次，以患者為中心的趨勢，例如擴大生育力保存的可及性、選擇性卵子冷凍以及第三方生殖服務的使用增加，正在重塑需求模式，並提升綜合諮詢和長期追蹤服務的重要性。第三，供應鏈韌性已成為策略重點。相關人員正在實現關鍵設備、冷凍保存材料和培養基供應商的多元化，以降低單一來源中斷的風險。最後，監管和報銷格局正在發生變化，付款人和政策制定者越來越重視基於價值的治療結果和公平的可及性。

評估近期美國關稅措施將如何影響生育治療價值鏈中的採購成本、供應鏈策略和臨床准入。

美國最近徵收的關稅為生育治療領域的製造商、經銷商和臨床終端用戶帶來了新的成本和物流方面的考慮。

對進口實驗室設備、專用耗材或零件提高關稅，可能會增加培養箱、顯微鏡、低溫系統以及培養基和冷凍保存試劑等設備的到岸成本。為應對此問題，製造商可能會採取本地組裝或替代籌資策略，以緩解利潤率下降。臨床醫生和診所可能面臨成本壓力，需要調整採購週期、優先採購可重複使用設備或重新協商服務契約，以維持營運預算。同時，傳統上整合國際產品線的經銷商可能會面臨產品組合和前置作業時間的變化。

此外，關稅往往會在中期內加速技術替代和供應商整合。擁有現有生產能力的國內製造商將獲得談判優勢，而國際供應商則可能憑藉自身競爭力消化關稅的影響並維持市場地位。政策制定者和產業協會可能會加強圍繞關鍵臨床用品關稅豁免的對話，相關人員應準備好提供數據證據，證明關稅對患者就醫和臨床療效的下游影響。最終，要有效應對關稅政策的累積影響，需要協調一致的籌資策略、情境規劃以及貫穿整個供應鏈的清晰溝通，以最大限度地減少對患者照護的干擾。

主導細分市場的洞察，將產品類型、治療方式、診斷路徑和最終用戶畫像與業務重點和投資選擇聯繫起來。

對市場區隔進行細緻入微的觀點，可以揭示臨床需求、資本密集度和耗材依賴性的交會點，從而為相關人員創造差異化的策略要務。

低溫系統、氣體分析儀、成像系統、培養箱、雷射系統、微操作系統、顯微鏡、卵子抽吸泵、精子分析系統和精子分離器各自都有不同的生命週期、維護和培訓要求，這些都會影響診所的運作模式和長期預算。配件、介質和消耗品（包括冷凍保存和培養基）具有經常性成本流，會影響供應商關係和庫存管理實踐。從治療類型的角度來看，交付模式差異很大：人工授精方法（例如子宮頸內、子宮內和子宮內方法）與輔助生殖技術（例如胚胎冷凍保存、體外受精、卵細胞質內單一精蟲顯微注射術和胚胎著床前基因診斷）形成對比；不孕症藥物—從克羅米芬檸檬酸鹽和來曲唑到促性腺激素分泌和二甲雙胍－需要藥理途徑和監測；節育手術，例如子子宮鏡檢查、腹腔鏡檢查、肌瘤摘除術和精索靜脈曲張治療，需要不同的轉診流程和手術全期資源。女性不孕症檢查依賴造影和排卵檢測，而男性不孕症評估則依賴血液檢查、精液分析和睪丸切片檢查，每種診斷途徑都決定了實驗室的優先事項和患者諮詢。最後，最終用戶——冷凍庫、生育診所、醫院和研究機構——各自的採購週期、監管義務和服務等級協議要求也各不相同。綜合以上細分框架，可以清楚看出，對專用設備、耗材供應保障、員工培訓和病患教育的投資將對業務產生最大的影響。

區域分析揭示了人口趨勢、報銷框架和當地能力將如何影響主要全球市場的採用率和可及性。

區域動態塑造了全球生育治療領域的需求模式、監管方式和競爭格局。

在美洲，私人診所網路和完善的報銷體系支撐著先進輔助生殖技術（ART）的高普及率，並維持著專用設備和耗材的持續市場。相反，在歐洲、中東和非洲，監管和報銷環境各不相同，領先的診所在都市區推動創新，而不同地區的醫療服務可近性也存在差異。在亞太地區，生育年齡延遲和家庭收入成長等人口趨勢正在擴大患者群體，並推動設備和耗材的快速普及。在所有地區，可藉鏡的最佳實踐包括對培訓、品管和冷凍保存材料的低溫運輸物流的投資。區域報銷政策、智慧財產權系統和本地製造能力將繼續是決定新技術推廣速度和醫療機構如何建構其服務組合的關鍵因素。

透過模組化產品平台、策略夥伴關係關係和基於證據的價值提案，打造市場領導的企業策略和競爭行動

對公司行為的策略性解讀突顯了其在創新、投資組合管理和市場競爭執行方面的差異化方法，而這反過來又決定了其競爭軌跡。

領先的製造商正日益重視模組化設備設計和基於平台的耗材生態系統，以鎖定與診所的長期合作關係，同時提供升級途徑以保護客戶的投資。服務供應商和診所營運商正在整合資源並建立策略聯盟，以擴大規模、規範臨床通訊協定並協商更有利的供應協議。同時，專注於單一創新（例如新型培養基配方或人工智慧影像處理系統）的參與企業正在探索與現有經銷商和實驗室網路建立合作關係，以加速檢驗和推廣。經銷商正在增加附加價值服務，例如培訓、預防性保養和整體擁有成本分析，以實現價格以外的差異化競爭優勢。總而言之，投資於監管策略、臨床證據產生和上市後真實世界結果追蹤的公司，可以透過減少實施摩擦並向臨床醫生和支付者展示實際利益來獲得競爭優勢。

為領導者提供切實可行的建議，以協調技術投資、供應鏈韌性、實證實踐和以患者為中心的服務，從而確保競爭優勢。

透過協調商業、臨床和營運策略，行業領導者可以利用當前趨勢，並在患者就醫和治療效果方面實現可衡量的改進。

首先，領導者應投資可擴展的實驗室自動化和培訓項目，以提高吞吐量並維持品質。將設備升級與標準化流程和基於能力的員工發展相結合，可以幫助診所減少週期波動並提高成本效益。其次，企業應實現供應鏈多元化，並尋求關鍵耗材和設備零件的近岸外包或雙重採購，以降低關稅和物流風險。第三，相關人員必須透過贊助強力的臨床研究和真實世界數據舉措來加強證據生成，以展示療效比較並為與支付方的對話提供資訊。最後，企業應擴展以患者為中心的服務，例如綜合諮詢、長期存檔服務和數位互動工具，以區分不同的診療路徑並在患者生命週期中創造價值。這些措施的結合將使醫療服務提供者和供應商能夠在保持成長的同時，提高臨床可靠性和病患滿意度。

採用透明的混合方法研究途徑，結合一手訪談、二手檢驗和三角測量，以提供可靠的產業洞察和策略指南。

本分析所依據的調查方法結合了定性和定量方法，以確保方法的穩健性和透明性，從而得出可操作的結論。

主要研究包括對臨床醫生、實驗室主任、採購經理以及醫療設備製造商和經銷商的高級管理人員進行結構化訪談，以獲取關於臨床工作流程、採購重點和新出現的痛點的第一手觀點。次要研究涵蓋同行評審的臨床文獻、監管文件、器械手冊和公開的政策文件，以檢驗技術性能特徵和合規性考慮因素。跨資料來源的三角驗證實現了對結論的交叉檢驗，方法論上的保障措施包括標準化的訪談指南、編碼員對定性輸入的整合以及對供應鏈和政策影響情境的敏感性分析。在適當情況下，將行業術語和細分框架映射到臨床路徑，以確保產品和治療類別與實際應用相符。儘管調查方法的局限性包括不同地區監管透明度的差異以及不斷變化的關稅和報銷政策可能帶來的短期不確定性，但這種混合方法仍然為戰略規劃和營運決策提供了可靠的基礎。

總結全文，重點在於技術採納、供應鏈韌性、實證實踐和以病人為中心的服務模式之間的策略一致性。

總之，由於技術的成熟、患者期望的改變以及對供應鏈和政策的日益嚴格審查，生育保健生態系統正處於曲折點。

積極協調實驗室自動化、人才培養、供應鏈韌性和實證醫學等方面投資的相關人員，將能夠以永續的成本結構提供更高品質的醫療保健服務。此外，差異化的以患者為中心的服務以及與支付方清晰的價值溝通，是擴大醫療服務覆蓋範圍和確保長期需求的關鍵槓桿。採購和策略夥伴關係的靈活性將決定哪些機構能夠在監管和收費環境不斷變化的情況下，保護淨利率並維持臨床服務的連續性。這些動態的綜合作用將為產品開發、臨床服務模式和商業性執行方面的創新創造機遇，並獎勵那些能夠將技術進步轉化為患者療效顯著改善的企業。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴大個人化基因篩檢的應用範圍，以提高試管嬰兒成功率並縮短治療週期
  • 利用穿戴式感測器技術開發一種非侵入式生殖監測設備，用於即時追蹤排卵情況
  • 擴大為癌症患者提供的生育力保存服務，將冷凍保存和不孕症諮詢結合
  • 將人工智慧融入胚胎選擇過程，以提高試管嬰兒診所的胚胎著床率
  • 生育診所和遠端醫療平台之間的合作日益增多，旨在改善遠距患者就醫和獲得支援。
  • 社會計劃生育和單親家庭趨勢推動了對卵子和精子捐贈庫的需求激增。
  • 家用荷爾蒙檢測套組的出現為傳統的臨床評估提供了經濟有效的替代方案。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依產品類型分類的生育治療市場

  • 配件
  • 裝置
    • 低溫系統
    • 氣體分析儀
    • 影像系統
    • 培養箱
    • 雷射系統
    • 微型機械手臂系統
    • 顯微鏡
    • 卵子吸泵
    • 精子分析系統
    • 精子分離裝置
  • 介質和耗材
    • 冷凍保存培養基
    • 培養基

第9章：依治療類型分類的不孕症治療市場

  • 人工授精
    • 子宮頸內人工授精
    • 輸卵管內授精
    • 子宮內人工授精
  • 輔助生殖技術（ART）
    • 胚胎冷凍保存
    • 體外受精（IVF）
    • 卵細胞質內單一精蟲顯微注射術（ICSI）
    • 胚胎著床前遺傳學診斷（PGD）
  • 生育藥物
    • 克羅米芬檸檬酸鹽
    • 促性腺激素分泌
    • 來曲唑
    • 二甲雙胍
  • 不孕症治療手術
    • 子宮鏡檢查
    • 腹腔鏡檢查
    • 子宮肌瘤切除術
    • 靜脈曲張修復
    • 靜脈曲張切除術

第10章：依診斷分類的不孕症治療市場

  • 女性不孕症
    • 造影（HSG）
    • 排卵測試
  • 男性不孕
    • 血液檢查
    • 精液分析
    • 睪丸切片檢查

第11章 以最終用戶分類的生育治療市場

  • 冷凍庫
  • 不孕不育診所
  • 醫院
  • 研究機構

第12章 生育治療市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 按群體分類的生育治療市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國生育治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Bayer AG
    • City Fertility Centre
    • CooperSurgical, Inc.
    • Cryoport Systems, LLC.
    • Embryolab
    • Ferring International Center SA
    • FUJIFILM Irvine Scientific, Inc.
    • Genea Group
    • IVI AMERICA, LLC
    • Merck KGaA
    • Monash IVF
    • New Hope Fertility Clinic
    • Nova IVF Fertility
    • NOW-fertility SA
    • Ovum Woman and Child specialty Hospital
    • ReproTech LLC
    • Seegene, Inc.
    • TMRW Life Sciences, Inc.
    • Vitrolife Sweden AB
Product Code: MRR-3E32260F8122

The Infertility Treatment Market is projected to grow by USD 14.30 billion at a CAGR of 11.61% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.93 billion
Estimated Year [2025] USD 6.58 billion
Forecast Year [2032] USD 14.30 billion
CAGR (%) 11.61%

A strategic introduction to how clinical advances, patient behavior shifts, and operational pressures are redefining infertility treatment priorities across healthcare stakeholders

The infertility treatment landscape is experiencing a convergence of clinical innovation, shifting patient demographics, and evolving care delivery models that together create both opportunity and complexity for providers, suppliers, and payers.

Clinically, advances in laboratory instrumentation, cryopreservation protocols, and adjunctive therapeutics are enhancing cycle efficiency and expanding treatment options for previously refractory cases. At the same time, patient expectations are changing; greater awareness, delayed childbearing, and demand for individualized care pathways are prompting providers to broaden service offerings and invest in patient experience. Economically, resource allocation pressures and reimbursement variability require clinics and hospitals to balance capital investments in equipment and consumables with operational efficiency gains. As a result, stakeholders must align clinical priorities with pragmatic business models to sustain growth and deliver measurable outcomes.

Transformative shifts redefining clinical practice, supply chain resilience, patient-centric services, and policy incentives across the infertility treatment ecosystem

The landscape of infertility treatment is shifting in ways that are transforming clinical practice, supply chains, and care models simultaneously.

First, laboratory automation and digital imaging are accelerating throughput while improving consistency of embryology workflows; these technological shifts are prompting clinics to rethink staffing models and training priorities. Second, patient-centric trends such as expanded access to fertility preservation, elective oocyte freezing, and greater uptake of third-party reproduction are reshaping demand patterns and increasing the importance of integrated counseling and long-term follow-up services. Third, supply chain resilience has become a strategic priority: stakeholders are diversifying suppliers for key equipment, cryomaterials, and media to reduce vulnerability to single-source disruptions. Finally, regulatory and reimbursement environments are evolving, with payers and policymakers increasingly focused on value-based outcomes and equitable access, which will influence clinical protocols and investment decisions going forward.

Assessing how recent United States tariff measures influence procurement costs, supply chain strategies, and clinical access within the infertility treatment value chain

Recent tariff actions originating from the United States have introduced new cost and logistical considerations for manufacturers, distributors, and clinical end users in the infertility treatment sector.

Higher duties on imported laboratory equipment, specialized consumables, or component parts can increase landed costs for instruments such as incubators, microscopes, and cryosystems, as well as for culture media and cryopreservation reagents. In response, manufacturers may pursue localized assembly or alternative sourcing strategies to mitigate margin erosion. Clinicians and clinics, facing incremental cost pressures, may adjust procurement cycles, prioritize multi-use equipment, or renegotiate service contracts to preserve operating budgets. In parallel, distributors that historically aggregated international product lines may see shifts in product mix and lead times; they will need to enhance inventory planning and provide clearer total-cost-of-ownership analyses to customers.

Moreover, tariffs tend to accelerate technology substitution and supplier consolidation in the medium term. Domestic producers with existing capacity may gain negotiating leverage, while international suppliers may absorb some duty impacts to retain market presence, depending on competitive dynamics. Policymakers and industry associations will likely intensify dialogue around tariff exemptions for critical clinical supplies, and stakeholders should prepare to provide data-driven evidence of downstream effects on patient access and clinical outcomes. Ultimately, managing the cumulative impact of tariff policy requires coordinated procurement strategies, scenario planning, and clear communication across the supply chain to minimize disruption to patient care.

Segment-driven insights that connect product categories, treatment modalities, diagnostic pathways, and end-user profiles to operational priorities and investment choices

A nuanced view of market segmentation reveals where clinical demand, capital intensity, and consumable dependency intersect and create differentiated strategic imperatives for stakeholders.

When examining product type, equipment categories drive capital expenditure decisions: cryosystems, gas analyzers, imaging systems, incubators, laser systems, micromanipulator systems, microscopes, ovum aspiration pumps, sperm analyzer systems, and sperm separation devices each have distinct lifecycle, maintenance, and training requirements that affect clinic operating models and long-term budgeting. Accessories and media and consumables, including cryopreservation media and culture media, present recurring expense streams and influence vendor relationships and inventory management practices. From the treatment type perspective, delivery models vary considerably: artificial insemination modalities such as intracervical, intratubal, and intrauterine approaches contrast with assisted reproductive technologies that encompass embryo cryopreservation, in vitro fertilization, intracytoplasmic sperm injection, and preimplantation genetic diagnosis; fertility drugs-ranging from clomiphene citrate and letrozole to gonadotropins and metformin-introduce pharmacologic pathways and monitoring needs; and fertility surgeries such as hysteroscopy, laparoscopy, myomectomy, and varicocele interventions create distinct referrals and perioperative resource requirements. Diagnostic segmentation further clarifies care pathways: female infertility investigations rely on hysterosalpingography and ovulation testing, while male infertility assessment centers on blood tests, semen analysis, and testicular biopsy, each diagnostic route dictating laboratory priorities and patient counseling. Finally, end users-cryobanks, fertility clinics, hospitals, and research institutes-exhibit different procurement cycles, regulatory obligations, and expectations for service-level agreements. Taken together, this segmentation framework highlights where investment in specialized equipment, consumable supply security, workforce training, and patient education will deliver the greatest operational leverage.

Regional landscape analysis revealing how demographic trends, reimbursement frameworks, and local capabilities influence adoption and access across principal global markets

Regional dynamics shape demand patterns, regulatory approaches, and competitive positioning across the global infertility treatment landscape.

In the Americas, private clinic networks and an established reimbursement mix support high adoption of advanced assisted reproductive technologies and a sustained market for both specialized equipment and culture media. Conversely, Europe, Middle East & Africa presents heterogeneous regulatory and reimbursement landscapes where leading clinics drive innovation in urban centers while access variability persists across jurisdictions; this region also sees growing interest in fertility preservation and cross-border care. In the Asia-Pacific region, demographic trends including delayed parenthood and rising household incomes are expanding the patient base, driving rapid adoption of equipment and consumables, and prompting domestic manufacturers and international suppliers to adapt product offerings for affordability and scalability. Across all regions, transplantable best practices include investments in training, quality control, and cold-chain logistics for cryopreservation materials. Regional reimbursement policies, intellectual property regimes, and local manufacturing capacity will continue to be primary determinants of how quickly new technologies scale and how providers structure service portfolios.

Corporate strategies and competitive behaviors that differentiate market leaders through modular product platforms, strategic partnerships, and evidence-driven value propositions

A strategic read of company behavior underscores differentiated approaches to innovation, portfolio management, and go-to-market execution that will determine competitive trajectories.

Leading manufacturers increasingly prioritize modular equipment designs and platform-based consumable ecosystems to lock in long-term clinic relationships while offering upgrade pathways that protect customer investments. Service providers and clinic operators are consolidating or forming strategic alliances to achieve scale, standardize clinical protocols, and negotiate more favorable supply contracts. At the same time, entrants focused on single innovations-such as novel culture media formulations or AI-enabled imaging systems-seek partnership models with established distributors and laboratory networks to accelerate validation and adoption. Distribution firms are enhancing value-add services, including training, preventative maintenance, and total-cost-of-ownership analyses, to differentiate beyond price. Across the board, companies that invest in regulatory strategy, clinical evidence generation, and post-market real-world outcome tracking will secure competitive advantage by reducing adoption friction and demonstrating tangible benefits to clinicians and payers.

Actionable recommendations for leaders to align technology investments, supply resilience, evidence generation, and patient-centered services to secure competitive advantage

Industry leaders can capitalize on current trends by aligning commercial, clinical, and operational strategies to deliver measurable improvements in patient access and outcomes.

First, leaders should invest in scalable laboratory automation and training programs that increase throughput while preserving quality; by pairing equipment upgrades with standardized protocols and competency-based staff development, clinics can reduce cycle variability and improve cost efficiency. Second, firms should diversify supply chains and pursue nearshoring or dual-sourcing arrangements for critical consumables and instrument components to mitigate tariff and logistics risks; contracts that include contingency inventory provisions and transparent lead-time commitments will enhance resilience. Third, stakeholders must strengthen evidence generation by sponsoring robust clinical studies and real-world data initiatives that demonstrate comparative effectiveness and inform payer conversations; these data will be pivotal in advancing reimbursement discussions and broadening access. Finally, companies should expand patient-centric services-such as integrated counseling, long-term preservation offerings, and digital engagement tools-to differentiate care pathways and capture value across the patient lifecycle. Taken together, these actions will enable providers and suppliers to sustain growth while improving clinical reliability and patient satisfaction.

Transparent mixed-methods research approach integrating primary interviews, secondary validation, and triangulation to underpin reliable sector insights and strategic guidance

The research approach underpinning this analysis combined qualitative and quantitative techniques to ensure a robust and transparent methodology that supports actionable conclusions.

Primary research included structured interviews with clinicians, laboratory directors, procurement managers, and senior executives across device manufacturers and distributers to capture firsthand perspectives on clinical workflows, procurement priorities, and emerging pain points. Secondary research encompassed peer-reviewed clinical literature, regulatory filings, device manuals, and publicly available policy documents to validate technical performance characteristics and compliance considerations. Triangulation across data sources enabled cross-verification of claims, and methodological safeguards included standardized interview guides, coder-based synthesis of qualitative inputs, and sensitivity analyses for supply chain and policy impact scenarios. Where appropriate, industry terminology and segmentation frameworks were mapped to clinical pathways to ensure that product and treatment categories aligned with real-world practice. Limitations acknowledged in the methodology include variability in regional regulatory transparency and the evolving nature of tariff and reimbursement policies, which can introduce short-term uncertainty; nonetheless, the mixed-methods approach provides a defensible foundation for strategic planning and operational decision-making.

Concluding synthesis that emphasizes strategic alignment across technology adoption, supply resilience, evidence generation, and patient-focused service models

In conclusion, the infertility treatment ecosystem is at an inflection point driven by technological maturation, changing patient expectations, and heightened supply chain and policy scrutiny.

Stakeholders that proactively align investments in laboratory automation, workforce development, supply chain resilience, and evidence generation will be positioned to deliver higher-quality care at sustainable cost structures. Furthermore, differentiated patient-centric services and clear value communication to payers will be critical levers for expanding access and securing long-term demand. As regulatory and tariff landscapes evolve, agility in sourcing and strategic partnerships will determine which organizations can both protect margins and preserve clinical continuity. The combination of these dynamics creates opportunities for innovation across product development, clinical service models, and commercial execution, and it rewards those who translate technological advances into demonstrable improvements in patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of personalized genetic screening to improve IVF success rates and reduce treatment cycles
  • 5.2. Development of noninvasive fertility monitoring devices using wearable sensor technology for real time ovulation tracking
  • 5.3. Expansion of fertility preservation services for cancer patients combining cryopreservation with oncofertility counseling
  • 5.4. Integration of artificial intelligence in embryo selection processes to enhance implantation rates in IVF clinics
  • 5.5. Rising collaborations between fertility clinics and telehealth platforms to increase remote patient access and support
  • 5.6. Surge in demand for egg and sperm donor banking driven by social fertility planning and single parenthood trends
  • 5.7. Emergence of at home hormone testing kits offering cost effective alternatives to traditional clinical assessments

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Infertility Treatment Market, by Product Type

  • 8.1. Accessories
  • 8.2. Equipment
    • 8.2.1. Cryosystems
    • 8.2.2. Gas Analyzers
    • 8.2.3. Imaging Systems
    • 8.2.4. Incubators
    • 8.2.5. Laser Systems
    • 8.2.6. Micromanipulator Systems
    • 8.2.7. Microscopes
    • 8.2.8. Ovum Aspiration Pumps
    • 8.2.9. Sperm Analyzer Systems
    • 8.2.10. Sperm Separation Devices
  • 8.3. Media & Consumables
    • 8.3.1. Cryopreservation Media
    • 8.3.2. Culture Media

9. Infertility Treatment Market, by Treatment Type

  • 9.1. Artificial Insemination
    • 9.1.1. Intracervical Insemination
    • 9.1.2. Intratubal Insemination
    • 9.1.3. Intrauterine Insemination
  • 9.2. Assisted Reproductive Technology (ART)
    • 9.2.1. Embryo Cryopreservation
    • 9.2.2. In Vitro Fertilization (IVF)
    • 9.2.3. Intracytoplasmic Sperm Injection (ICSI)
    • 9.2.4. Preimplantation Genetic Diagnosis (PGD)
  • 9.3. Fertility Drugs
    • 9.3.1. Clomiphene Citrate
    • 9.3.2. Gonadotropins
    • 9.3.3. Letrozole
    • 9.3.4. Metformin
  • 9.4. Fertility Surgeries
    • 9.4.1. Hysteroscopy
    • 9.4.2. Laparoscopy
    • 9.4.3. Myomectomy
    • 9.4.4. Varicocele Repair
    • 9.4.5. Varicocelectomy

10. Infertility Treatment Market, by Diagnosis

  • 10.1. Female Infertility
    • 10.1.1. Hysterosalpingography (HSG)
    • 10.1.2. Ovulation Testing
  • 10.2. Male Infertility
    • 10.2.1. Blood Tests
    • 10.2.2. Semen Analysis
    • 10.2.3. Testicular Biopsy

11. Infertility Treatment Market, by End User

  • 11.1. Cryobanks
  • 11.2. Fertility Clinics
  • 11.3. Hospitals
  • 11.4. Research Institutes

12. Infertility Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Infertility Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Infertility Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Bayer AG
    • 15.3.2. City Fertility Centre
    • 15.3.3. CooperSurgical, Inc.
    • 15.3.4. Cryoport Systems, LLC.
    • 15.3.5. Embryolab
    • 15.3.6. Ferring International Center S.A.
    • 15.3.7. FUJIFILM Irvine Scientific, Inc.
    • 15.3.8. Genea Group
    • 15.3.9. IVI AMERICA, LLC
    • 15.3.10. Merck KGaA
    • 15.3.11. Monash IVF
    • 15.3.12. New Hope Fertility Clinic
    • 15.3.13. Nova IVF Fertility
    • 15.3.14. NOW-fertility SA
    • 15.3.15. Ovum Woman and Child specialty Hospital
    • 15.3.16. ReproTech LLC
    • 15.3.17. Seegene, Inc.
    • 15.3.18. TMRW Life Sciences, Inc.
    • 15.3.19. Vitrolife Sweden AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFERTILITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS INFERTILITY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA INFERTILITY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. INFERTILITY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. INFERTILITY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INFERTILITY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INFERTILITY TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INFERTILITY TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ACCESSORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ACCESSORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ACCESSORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOSYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOSYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOSYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOSYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOSYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOSYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GAS ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GAS ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GAS ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GAS ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GAS ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GAS ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INCUBATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INCUBATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INCUBATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INCUBATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INCUBATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INCUBATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LASER SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LASER SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LASER SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LASER SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LASER SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LASER SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROMANIPULATOR SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROMANIPULATOR SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROMANIPULATOR SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROMANIPULATOR SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROMANIPULATOR SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROMANIPULATOR SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROSCOPES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROSCOPES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROSCOPES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROSCOPES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROSCOPES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROSCOPES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVUM ASPIRATION PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVUM ASPIRATION PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVUM ASPIRATION PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVUM ASPIRATION PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVUM ASPIRATION PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVUM ASPIRATION PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM ANALYZER SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM ANALYZER SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM ANALYZER SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM ANALYZER SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM ANALYZER SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM ANALYZER SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM SEPARATION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM SEPARATION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM SEPARATION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM SEPARATION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM SEPARATION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM SEPARATION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOPRESERVATION MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOPRESERVATION MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOPRESERVATION MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOPRESERVATION MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOPRESERVATION MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOPRESERVATION MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CULTURE MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CULTURE MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CULTURE MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CULTURE MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CULTURE MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CULTURE MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACERVICAL INSEMINATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACERVICAL INSEMINATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACERVICAL INSEMINATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACERVICAL INSEMINATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACERVICAL INSEMINATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACERVICAL INSEMINATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRATUBAL INSEMINATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRATUBAL INSEMINATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRATUBAL INSEMINATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRATUBAL INSEMINATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRATUBAL INSEMINATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRATUBAL INSEMINATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EMBRYO CRYOPRESERVATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EMBRYO CRYOPRESERVATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EMBRYO CRYOPRESERVATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EMBRYO CRYOPRESERVATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EMBRYO CRYOPRESERVATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EMBRYO CRYOPRESERVATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IN VITRO FERTILIZATION (IVF), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IN VITRO FERTILIZATION (IVF), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IN VITRO FERTILIZATION (IVF), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IN VITRO FERTILIZATION (IVF), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IN VITRO FERTILIZATION (IVF), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IN VITRO FERTILIZATION (IVF), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION (ICSI), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION (ICSI), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION (ICSI), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION (ICSI), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION (ICSI), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION (ICSI), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS (PGD), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS (PGD), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS (PGD), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS (PGD), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS (PGD), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS (PGD), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CLOMIPHENE CITRATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CLOMIPHENE CITRATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CLOMIPHENE CITRATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CLOMIPHENE CITRATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CLOMIPHENE CITRATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CLOMIPHENE CITRATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GONADOTROPINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GONADOTROPINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GONADOTROPINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GONADOTROPINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GONADOTROPINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GONADOTROPINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LETROZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LETROZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LETROZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LETROZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LETROZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LETROZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY METFORMIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY METFORMIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY METFORMIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY METFORMIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY METFORMIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY METFORMIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LAPAROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LAPAROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LAPAROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LAPAROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LAPAROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LAPAROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MYOMECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MYOMECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MYOMECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MYOMECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MYOMECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MYOMECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELE REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELE REPAIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELE REPAIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELE REPAIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELE REPAIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELE REPAIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSALPINGOGRAPHY (HSG), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSALPINGOGRAPHY (HSG), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSALPINGOGRAPHY (HSG), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSALPINGOGRAPHY (HSG), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSALPINGOGRAPHY (HSG), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSALPINGOGRAPHY (HSG), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVULATION TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVULATION TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVULATION TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVULATION TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVULATION TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVULATION TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY BLOOD TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SEMEN ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SEMEN ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SEMEN ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SEMEN ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SEMEN ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SEMEN ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TESTICULAR BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TESTICULAR BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TESTICULAR BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TESTICULAR BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TESTICULAR BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TESTICULAR BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOBANKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOBANKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOBANKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOBANKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOBANKS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOBANKS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY RESEARCH I